TCT-113 Adverse Events After Left Atrial Appendage Closure: Lessons Learned From the Manufacturer and User Facility Device Experience (MAUDE) Database.

Swaiman Singh,Alexis K. Okoh,Christoph Sossou,Joseph Heaton,Mayal Sandhu,Ritu Chakrabarti,Rameez Rao,Rajiv Tayal,Najam Wasty,Sergio Waxman

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2019）

引用 1|浏览10

暂无评分

摘要

Early randomized trials demonstrated that left atrial appendage closure (LAAC) with an LAAC device was equivalent to warfarin for preventing stroke in atrial fibrillation. There are limited published post-approval surveillance data on LAAC devices. We analyzed the U.S. Food and Drug Administration (

查看译文

关键词

left atrial appendage closure,adverse events

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要